SymBio Completes Patient Enrollment for Mantle Cell Lymphoma in Bendamustine Phase II Clinical Study
News Jul 07, 2008
SymBio Pharmaceuticals Limited has completed target enrollment of patients with mantle cell lymphoma for an ongoing Phase II clinical study of Bendamustine after completing enrollment of patients with indolent non-Hodgkin’s lymphoma (iNHL). The Japan study is being conducted at 18 institutions nationwide since its initiation in December, 2007.
The company intends to collect efficacy and safety data in preparation for NDA filing. Due to completion of enrollment for iNHL and mantle cell lymphoma (MCL) patients earlier than originally planned, the company has expedited its development timeline of Bendamustine, with submission of the NDA now expected in the 4th quarter of 2009.
SymBio has acquired exclusive rights for the development and commercialization of bendamustine HCl in Japan, China (Hong Kong), Taiwan, Korea and Singapore from Astellas Pharma GmbH (currently, Astellas Deutschland GmbH, Munchen, Germany).
In Germany, bendamustine HCl is used as an anticancer drug under the brand name “Ribomustin.” On March 20, 2008, Cephalon, Inc. (Frazer, PA) received NDA approval from US FDA for TREANDA (bendamustine HCl) in the treatment of patients with chronic lymphocytic leukemia (CLL).
Cephalon has filed a supplemental NDA with FDA for use in patients with indolent low-grade NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen, and expects to receive FDA approval by the 4th quarter of this year. MAAs have also been filed with EMEA for use of bendamustine HCl in the treatment of iNHL, CLL and multiple myeloma (MM) in 13 European countries, excluding Germany and Bulgaria.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018